Sacubitril/Valsartan
- Generic Name
- Sacubitril/Valsartan
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
⑴用于在有慢性心力衰竭(NYHA类别II-IV)患者中减低对心力衰竭的心血管死亡及住院治疗慢性心力衰竭和射血分数降低。本品通常与其他心力衰竭治疗结合，代替一种ACE抑制药或其他血管紧张素II受体阻断药。
⑵用于治疗原发性高血压.
- Associated Conditions
- -
- Associated Therapies
- -
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Sichuan Academy of Medical Sciences
- Target Recruit Count
- 297
- Registration Number
- NCT06501651
- Locations
- 🇨🇳
Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
- Conditions
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Heart Center Research, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06218199
- Locations
- 🇺🇸
Heart Center Research, LLC, Huntsville, Alabama, United States
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT06149104
- Locations
- 🇯🇵
Novartis Investigative Site, Toyama, Japan
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 720
- Registration Number
- NCT06142383
- Locations
- 🇺🇸
SEC Clinical Research Research, Dothan, Alabama, United States
🇺🇸Heart Center Research Llc ., Huntsville, Alabama, United States
🇺🇸Pima Heart And Vascular Clin Rch Research, Tucson, Arizona, United States
Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9230
- Registration Number
- NCT05613140
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2022-09-19
- Target Recruit Count
- 138
- Registration Number
- NCT05545059
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 924
- Registration Number
- NCT05448872
- Locations
- 🇮🇹
Novartis Investigative Site, Trieste, Italy
Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-05-24
- Target Recruit Count
- 121
- Registration Number
- NCT05387967
- Locations
- 🇵🇰
National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan
Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Target Recruit Count
- 168
- Registration Number
- NCT05366101
- Locations
- 🇬🇧
Newcastle NHS, Newcastle, United Kingdom
Enhancing the Natriuretic Peptide System in HFpEF
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Horng Chen
- Target Recruit Count
- 60
- Registration Number
- NCT05279742
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.